@Article{,
AUTHOR = {Suraj Pursnani, Necole M. Streeper},
TITLE = {Case of drug-induced kidney stone from overuse of phenazopyridine},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {31},
YEAR = {2024},
NUMBER = {3},
PAGES = {11911--11913},
URL = {http://www.techscience.com/CJU/v31n3/59592},
ISSN = {1488-5581},
ABSTRACT = {Drug-induced nephrolithiasis represents only 1%-2% of
stone cases. Here we focus on drugs capable of crystallizing
and forming stone, specifically phenazopyridine
(Pyridium/Azo). This is a case of a patient who presented
with a stone conglomerate in the right proximal ureter and underwent definitive treatment. Interestingly, the
stone had a purple hue with FTIR spectroscopy showing
stone composition of calcium oxalate (monohydrate and
dihydrate) and a material resembling phenazopyridine.
We retrospectively learned that she used multiple extended
courses of phenazopyridine over 3 months.},
DOI = {}
}